AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Huiying Han, Morgann Klink, Kalyani Daita, Rebecca Filippi, Marcello Marelli, Jin Niu, Ryan Fleming, Andrea Christmas, Steve Arbitman, Francesca Casano, Shraddha Kale, Mark Hutchinson, Qun Du, Reena Varkey, Karyn Folliot, Chandrika Kannadka, Harini Shandilya, Jaqueline Picache, Stefanie Meyer, Rebecca Sargeant, Nicolas Damond, John Meekin, Christina Vasalou, Jennifer Wheeler, Thomas Linke, Ekaterina Jahn, Connor Hall, Balakumar Vijayakrishnan, Maximillian Lee, Ali Saleh, Kimberly Cook, Benedicte Recolin, Jay Harper, John Bullen, Krista Kinneer, Edward Rosfjord, Arthur Shaffer, Elaine Hurt, Ken Wood, Puja Sapra
Institutions: AstraZeneca (United States), AstraZeneca (United Kingdom)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417006189
Cites:
Cited by:
Related to: